Edgewise Therapeutics (EWTX) CSO exercises 200K options and sells 200K shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Edgewise Therapeutics, Inc. reported that Chief Scientific Officer Alan J. Russell executed an exercise-and-sell transaction involving company stock. He exercised stock options to acquire a total of 200,000 shares of common stock, including 69,648 shares at an exercise price of $0.18 per share and 130,352 shares at an exercise price of $0.45 per share. On the same date, he sold 69,648 shares at an average price of $39.4089 per share and 130,352 shares at an average price of $39.4060 per share in open-market transactions, for total sales of 200,000 shares. Following these transactions, he directly holds 94,203 shares of common stock and retains 1,077,717 stock options with a $0.18 exercise price expiring on June 27, 2032.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 200,000 shares ($7,881,402)
Net Sell
6 txns
Insider
Russell Alan J
Role
Chief Scientific Officer
Sold
200,000 shs ($7.88M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 130,352 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 69,648 | $0.00 | -- |
| Exercise | Common Stock | 130,352 | $0.45 | $59K |
| Exercise | Common Stock | 69,648 | $0.18 | $13K |
| Sale | Common Stock | 130,352 | $39.406 | $5.14M |
| Sale | Common Stock | 69,648 | $39.4089 | $2.74M |
Holdings After Transaction:
Stock Option (Right to Buy) — 0 shares (Direct, null);
Common Stock — 154,907 shares (Direct, null)
Footnotes (1)
- Includes 107 shares purchased on November 15, 2025 and 1,048 shares purchased on May 15, 2026 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $38.77 to $40.81, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $38.77 to $40.905, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. 1/48th of the shares subject to the option vest each month beginning on September 10, 2018, subject to the Reporting Person continuing as a service provider through each vest date. 1/48th of the shares subject to the option vest each month beginning on July 27, 2017, subject to the Reporting Person continuing as a service provider through each vest date.
Key Figures
Common shares sold: 200,000 shares
Average sale prices: $39.4089 and $39.4060 per share
Options exercised: 200,000 shares
+3 more
6 metrics
Common shares sold
200,000 shares
Open-market sales on July 1, 2026
Average sale prices
$39.4089 and $39.4060 per share
Two sale tranches of 69,648 and 130,352 shares
Options exercised
200,000 shares
69,648 at $0.18 and 130,352 at $0.45 per share
Shares held after transactions
94,203 shares
Common stock directly owned post-transaction
Options remaining at $0.18
1,077,717 options
Stock options with $0.18 exercise price expiring June 27, 2032
Exercised $0.45 options remaining
0 options
Stock options with $0.45 exercise price after full exercise
Key Terms
Stock Option (Right to Buy), average price, Employee Stock Purchase Plan, vest, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
average price financial
"The price reported in column 4 is an average price."
Employee Stock Purchase Plan financial
"purchased ... pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan."
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
vest financial
"1/48th of the shares subject to the option vest each month"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
What insider transactions did Edgewise Therapeutics (EWTX) disclose for Alan J. Russell?
Edgewise Therapeutics disclosed that Chief Scientific Officer Alan J. Russell exercised options for 200,000 shares of common stock and sold 200,000 shares in open-market transactions on the same date, reflecting an exercise-and-sell pattern rather than a standalone open-market purchase.
What stock options did Alan J. Russell exercise in this Edgewise Therapeutics (EWTX) Form 4?
He exercised two stock option grants: 69,648 options with a $0.18 per share exercise price and 130,352 options with a $0.45 per share exercise price. These option exercises converted derivative positions into 200,000 shares of common stock before the related open-market sales.
Does Alan J. Russell still hold Edgewise Therapeutics (EWTX) stock options after these transactions?
Yes. After exercising 130,352 options at $0.45 per share to zero, he continues to hold 1,077,717 stock options with a $0.18 per share exercise price. These options relate to common stock and are scheduled to expire on June 27, 2032.
How do the Edgewise Therapeutics (EWTX) Form 4 footnotes describe Alan J. Russell’s transactions?
The footnotes note that the reported sale prices are averages across multiple trades within specified ranges and that the underlying options vest monthly over four years, contingent on continued service, clarifying both pricing mechanics and the original vesting structure of the exercised stock options.